A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Can human-centered design bring more humanity into health care?

by Ben Jonash, Principal, Deloitte Consulting LLP

The words “putting patients first”—or some variation—can be seen on the walls or in the promotional literature of nearly every health care company in the country. I don’t question the intent, but if we are going to help solve health care’s most entrenched challenges, this idea should be at the heart of our business.

Human-centered design is a mindset and discipline that puts the person,

Read more

Dr. Robot will see you now: Could artificial intelligence replace your doctor?

by Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP

In the original Star Trek series of the late 1960s, Dr. Leonard “Bones” McCoy relied on technology to diagnose and treat every health condition the crew encountered. But the tricorder didn’t replace the doctor. It enhanced his abilities.

At this week’s Digital Medtech Conference in San Francisco, I will take part in a panel discussion on the benefits and risks of AI and technology in health care.

Read more

Do health-management programs work? Health plan execs might have no idea

by David Veroff, Specialist Leader, Deloitte Consulting LLP

Health plans have been investing in care management, wellness, and population health programs for decades. While the size and scope of health-management programs vary by company, many face the same challenge: The ability to accurately determine a return on investment (ROI).

The definition of health management is broad. It can include everything that helps a member effectively manage a chronic condition.

Read more

Four market realities new pharmaceutical commercial models should consider addressing

by Jeff Ford, Principal, Deloitte Consulting LLP, Principal, Deloitte Consulting LLP

The US pharmaceutical industry’s commercial market has historically been the Wild West. Under a fee-for-service environment, physicians and their patients made many of the care decisions with few restrictions. However, the changing health care landscape, including the move to a value-based health care system, has changed the ability of manufacturers to drive growth through the lever of price.   

Read more

Expanding Medical Affairs could help restore trust, demonstrate value of biopharma organizations and products

by Tom Yang, Principal, Monitor Deloitte, Deloitte Consulting, LLP

Within biopharmaceutical companies, Medical Affairs has often been seen as a necessity, but not necessarily core. This unit is typically neither responsible for the development nor commercialization of new drugs.

We see untapped value in Medical Affairs for biopharma, but few companies have been able to capture it. Here are three areas where Medical Affairs could enhance value for biopharma companies:

  • Restoring trust: In an environment that has commonly grown skeptical of large biopharma companies,
Read more

When the music changes, so does the dance: Time for biopharma to get in step with value-based contracting

by Joseph M. Coppola, Managing Director, Life Sciences Commercial and Market Access Practice Leader, Deloitte Consulting LLP

There is a well-known African proverb, “When the music changes, so does the dance.” I was thinking about this recently when I was a panelist on SAP’s Changing the Game in Life Sciences radio program, “Outcome-Based Pricing: Cure for An Ailing Healthcare Industry.” The moderator asked me for a quote that I felt best represented what was happening in the industry related to emerging pricing and payment models.

Read more